Company profile
Sana Biotechnology, Inc.
NASDAQ:SANABiotechnology: Biological Products (No Diagnostic Substances)
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| Persicabtagene Lemgedleucel | phase1 | — | 2 | active |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (3)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT06285422 | phase1 | active_not_recruiting | 2024-04-18 | 2025-12-01 | Sana Biotechnology | Study Evaluating SC262 in Subjects With r/r Non-Hodgkin's Lymphoma (VIVID) |
| NCT06294236 | phase1 | active_not_recruiting | 2024-04-29 | 2027-12-01 | Sana Biotechnology | Study Evaluating SC291 in Subjects With Severe r/r B-cell Mediated Autoimmune Diseases (GLEAM) |
| NCT05878184 | phase1 | active_not_recruiting | 2023-05-02 | 2025-11-04 | Sana Biotechnology | Study Evaluating SC291 in Subjects With r/r B-cell Malignancies (ARDENT) |
FDA applications (0)
No records yet.